Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy
- PMID: 8562235
- PMCID: PMC484070
- DOI: 10.1136/hrt.74.5.508
Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy
Abstract
Background: To determine the incidence and prognosis of left ventricular dilatation and systolic dysfunction in 139 patients with hypertrophic cardiomyopathy during long term follow up.
Methods: Left ventricular chamber dilatation and systolic dysfunction (both together referred to as left ventricular chamber dilatation) were determined echocardiographically. Chamber dilatation was defined as an increase in the left ventricular end diastolic diameter of > 2% per year combined with a decrease in midventricular systolic fractional shortening of > 2% per year of follow up [10.3 (SD 6) years]. The predictive value for left ventricular chamber dilatation of clinical, invasive, and echocardiographic variables and its prognosis were assessed.
Results: In 119 of 139 individuals (86%), left ventricular chamber size and systolic function remained stable (group 1), and in 20/139 patients (14%) left ventricular chamber dilatation occurred during follow up (group 2). At baseline examination, symptoms such as dyspnoea and syncope occurred less often in group 1 than in group 2; New York Heart Association classification was lower in group 1 than in group 2 (P = 0.001). Left ventricular mass index relative to sex specific normal values was increased by 18% in group 1 and by 41% in group 2 (P = 0.04). Cumulative survival rates were slightly although not significantly higher in group 1 than in group 2. Event-free survival was significantly higher in group 1 than in group 2 (P < 0.05).
Conclusions: (1) The development of left ventricular chamber dilatation and systolic dysfunction in hypertrophic cardiomyopathy occurs in approximately 1.5% of the patients per year. (2) Factors associated with left ventricular dilatation are dyspnoea, syncope, a higher functional classification, and a higher degree of left ventricular hypertrophy. (3) Patients with chamber dilatation have a worse prognosis than those without, particularly regarding quality of life.
Similar articles
-
Reversal of dilated to hypertrophic cardiomyopathy after alcohol abstinence.Clin Cardiol. 1998 May;21(5):365-7. doi: 10.1002/clc.4960210515. Clin Cardiol. 1998. PMID: 9595223 Free PMC article.
-
Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.Rev Port Cardiol. 2004 Dec;23(12):1557-82. Rev Port Cardiol. 2004. PMID: 15732658 English, Portuguese.
-
Risk factors for systolic dysfunction and ventricular dilatation in hypertrophic cardiomyopathy.Int J Cardiol. 1994 May;44(3):225-33. doi: 10.1016/0167-5273(94)90286-0. Int J Cardiol. 1994. PMID: 8077068 Review.
-
A standard echocardiographic and tissue Doppler study of morphological and functional findings in children with hypertrophic cardiomyopathy compared to those with left ventricular hypertrophy in the setting of Noonan and LEOPARD syndromes.Cardiol Young. 2008 Dec;18(6):575-80. doi: 10.1017/S104795110800320X. Epub 2008 Oct 9. Cardiol Young. 2008. PMID: 18842161
-
[The echocardiographic examination in adult cardiomyopathy].Arch Mal Coeur Vaiss. 1998 Dec;91(12 Suppl):35-42. Arch Mal Coeur Vaiss. 1998. PMID: 9891820 Review. French.
Cited by
-
Subtypes and Mechanisms of Hypertrophic Cardiomyopathy Proposed by Machine Learning Algorithms.Life (Basel). 2022 Oct 9;12(10):1566. doi: 10.3390/life12101566. Life (Basel). 2022. PMID: 36294999 Free PMC article.
-
Reversal of dilated to hypertrophic cardiomyopathy after alcohol abstinence.Clin Cardiol. 1998 May;21(5):365-7. doi: 10.1002/clc.4960210515. Clin Cardiol. 1998. PMID: 9595223 Free PMC article.
-
Compensated hypertrophy of cardiac ventricles in aged transgenic FVB/N mice overexpressing calsequestrin.Mol Cell Biochem. 2003 Jan;242(1-2):19-25. Mol Cell Biochem. 2003. PMID: 12619861
-
Echocardiographic Predictors of All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy following Pacemaker Implantation.Cardiol Res Pract. 2020 Feb 14;2020:2923767. doi: 10.1155/2020/2923767. eCollection 2020. Cardiol Res Pract. 2020. PMID: 32148950 Free PMC article.
-
Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction.ESC Heart Fail. 2021 Dec;8(6):5513-5522. doi: 10.1002/ehf2.13653. Epub 2021 Oct 27. ESC Heart Fail. 2021. PMID: 34708560 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources